Souhaitez-vous accéder aux communiqués récents ?

Eye Care Associates of Northeastern Ohio has selected Nextech’s ophthalmic platform to automate workflows and improve the patient care experience.

Nextech's ophthalmic platform has been selected by Pacific Eye Associates to automate operational and clinical workflows, and increase speed to revenue.

Atavistik Bio presents preclinical data on precision oncology development candidate, ATV-1601, a selective allosteric AKT1 E17K small molecule inhibitor.

Austin, TX, USA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Lithium-Sulfur Battery Market Size, Trends and Insights By Component (Anode,...

Wyatt Surgery Center has selected Nextech’s platform with fully integrated revenue cycle management capabilities to maximize revenue across locations.

AKT1 E17K mutation is a clinically validated oncogene that impacts greater than 40,000 cancer patients per year in the United States, with the highest prevalence in breast, endometrial, and prostate...

Nextech Chief Medical Officer Dr. Jason Handza will present on the responsible use of artificial intelligence (AI) in healthcare at Eyecelerator.

Nextech’s ophthalmology platform has been selected by Key-Whitman Eye Center to serve its multiple locations in the Dallas-Fort Worth metroplex.

Nextech announces the opening of registration for EDGE 2025, the company’s annual user conference, to be held March 6-8 in Orlando, Fla.

Nextech's leading payments platform has new capabilities to improve patient experience and increase speed to revenue for specialty practices.